TY - CHAP A1 - Abendschein, Robin A1 - Desai, Shital A1 - Astell, Arlene J. T1 - Towards Accessibility Guidelines for the Metaverse : A Synthesis of Recommendations for People Living With Dementia T2 - Conference on Human Factors in Computing Systems (CHI’23) : Workshop "Towards an Inclusive and Accessible Metaverse" N2 - Given the growing interest of corporate stakeholders in Metaverse applications, there is a need to understand accessibility of these technologies for marginalized populations such as people living with dementia to ensure inclusive design of Metaverse applications. We assessed the accessibility of extended reality technology for people living with mild cognitive impairment and dementia to develop accessibility guidelines for these technologies. We used four strategies to synthesize evidence for barriers and facilitators of accessibility: (1) Findings from a non-systematic literature review, (2) guidelines from well-researched technology, (3) exploration of selected mixed reality technologies, and (4) observations from four sessions and video data of people living with dementia using mixed reality technologies. We utilized template analysis to develop codes and themes towards accessibility guidelines. Future work can validate our preliminary findings by applying them on video recordings or testing them in experiments. KW - CHI Conference KW - Accessibility KW - Metaverse KW - extended reality KW - dementia KW - cognitive impairment KW - Human-centered computing / Access KW - Human-centered computing / Human computer interaction (HCI) / Interaction paradigms / Mixed / augmented reality KW - Human-centered computing / Human computer interaction (HCI) / Interaction paradigms / Virtual reality KW - Human-centered computing / Human computer interaction (HCI) / Interactiondevices KW - Human-centered computing / Human computerinteraction (HCI) / Interaction techniques Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-320199 UR - https://sites.google.com/view/accessiblemetaverse ER - TY - JOUR A1 - Traub, Jan A1 - Otto, Markus A1 - Sell, Roxane A1 - Göpfert, Dennis A1 - Homola, György A1 - Steinacker, Petra A1 - Oeckl, Patrick A1 - Morbach, Caroline A1 - Frantz, Stefan A1 - Pham, Mirko A1 - Störk, Stefan A1 - Stoll, Guido A1 - Frey, Anna T1 - Serum phosphorylated tau protein 181 and neurofilament light chain in cognitively impaired heart failure patients JF - Alzheimer's Research & Therapy N2 - Background Chronic heart failure (HF) is known to increase the risk of developing Alzheimer’s dementia significantly. Thus, detecting and preventing mild cognitive impairment, which is common in patients with HF, is of great importance. Serum biomarkers are increasingly used in neurological disorders for diagnostics, monitoring, and prognostication of disease course. It remains unclear if neuronal biomarkers may help detect cognitive impairment in this high-risk population. Also, the influence of chronic HF and concomitant renal dysfunction on these biomarkers is not well understood. Methods Within the monocentric Cognition.Matters-HF study, we quantified the serum levels of phosphorylated tau protein 181 (pTau) and neurofilament light chain (NfL) of 146 extensively phenotyped chronic heart failure patients (aged 32 to 85 years; 15.1% women) using ultrasensitive bead-based single-molecule immunoassays. The clinical work-up included advanced cognitive testing and cerebral magnetic resonance imaging (MRI). Results Serum concentrations of NfL ranged from 5.4 to 215.0 pg/ml (median 26.4 pg/ml) and of pTau from 0.51 to 9.22 pg/ml (median 1.57 pg/ml). We detected mild cognitive impairment (i.e., T-score < 40 in at least one cognitive domain) in 60% of heart failure patients. pTau (p = 0.014), but not NfL, was elevated in this group. Both NfL (ρ = − 0.21; p = 0.013) and pTau (ρ = − 0.25; p = 0.002) related to the cognitive domain visual/verbal memory, as well as white matter hyperintensity volume and cerebral and hippocampal atrophy. In multivariable analysis, both biomarkers were independently influenced by age (T = 4.6 for pTau; T = 5.9 for NfL) and glomerular filtration rate (T = − 2.4 for pTau; T = − 3.4 for NfL). Markers of chronic heart failure, left atrial volume index (T = 4.6) and NT-proBNP (T = 2.8), were further cardiological determinants of pTau and NfL, respectively. In addition, pTau was also strongly affected by serum creatine kinase levels (T = 6.5) and ferritin (T = − 3.1). Conclusions pTau and NfL serum levels are strongly influenced by age-dependent renal and cardiac dysfunction. These findings point towards the need for longitudinal examinations and consideration of frequent comorbidities when using neuronal serum biomarkers. KW - Alzheimer’s dementia KW - heart failure KW - cognitive impairment KW - neurofilament light chain KW - phosphorylated tau protein KW - renal function KW - age Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-300515 VL - 14 ER - TY - JOUR A1 - Palkovits, Miklós A1 - Šebeková, Katarína A1 - Klenovics, Kristina Simon A1 - Kebis, Anton A1 - Fazeli, Gholamreza A1 - Bahner, Udo A1 - Heidland, August T1 - Neuronal Activation in the Central Nervous System of Rats in the Initial Stage of Chronic Kidney Disease-Modulatory Effects of Losartan and Moxonidine JF - PLoS ONE N2 - The effect of mild chronic renal failure (CRF) induced by 4/6-nephrectomy (4/6NX) on central neuronal activations was investigated by c-Fos immunohistochemistry staining and compared to sham-operated rats. In the 4/6 NX rats also the effect of the angiotensin receptor blocker, losartan, and the central sympatholyticum moxonidine was studied for two months. In serial brain sections Fos-immunoreactive neurons were localized and classified semiquantitatively. In 37 brain areas/nuclei several neurons with different functional properties were strongly affected in 4/6NX. It elicited a moderate to high Fos-activity in areas responsible for the monoaminergic innervation of the cerebral cortex, the limbic system, the thalamus and hypothalamus (e.g. noradrenergic neurons of the locus coeruleus, serotonergic neurons in dorsal raphe, histaminergic neurons in the tuberomamillary nucleus). Other monoaminergic cell groups (A5 noradrenaline, C1 adrenaline, medullary raphe serotonin neurons) and neurons in the hypothalamic paraventricular nucleus (innervating the sympathetic preganglionic neurons and affecting the peripheral sympathetic outflow) did not show Fos-activity. Stress- and pain-sensitive cortical/subcortical areas, neurons in the limbic system, the hypothalamus and the circumventricular organs were also affected by 4/6NX. Administration of losartan and more strongly moxonidine modulated most effects and particularly inhibited Fos-activity in locus coeruleus neurons. In conclusion, 4/6NX elicits high activity in central sympathetic, stress- and pain-related brain areas as well as in the limbic system, which can be ameliorated by losartan and particularly by moxonidine. These changes indicate a high sensitivity of CNS in initial stages of CKD which could be causative in clinical disturbances. KW - brain natriuretic peptide KW - kidneys KW - cognitive impairment KW - central nervous system KW - chronic kidney disease KW - neurons KW - homeostasis KW - blood pressure Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-130108 VL - 8 IS - 6 ER - TY - JOUR A1 - Reimann, Hauke A1 - Stopper, Helga A1 - Polak, Thomas A1 - Lauer, Martin A1 - Herrmann, Martin J. A1 - Deckert, Jürgen A1 - Hintzsche, Henning T1 - Micronucleus frequency in buccal mucosa cells of patients with neurodegenerative diseases JF - Scientific Reports N2 - Neurodegenerative diseases show an increase in prevalence and incidence, with the most prominent example being Alzheimer's disease. DNA damage has been suggested to play a role in the pathogenesis, but the exact mechanisms remain elusive. We enrolled 425 participants with and without neurodegenerative diseases and analyzed DNA damage in the form of micronuclei in buccal mucosa samples. In addition, other parameters such as binucleated cells, karyolytic cells, and karyorrhectic cells were quantified. No relevant differences in DNA damage and cytotoxicity markers were observed in patients compared to healthy participants. Furthermore, other parameters such as lifestyle factors and diseases were also investigated. Overall, this study could not identify a direct link between changes in buccal cells and neurogenerative diseases, but highlights the influence of lifestyle factors and diseases on the human buccal cytome. KW - peripheral-blood lymphocytes KW - Alzheimers disease KW - DNA damage KW - cognitive impairment KW - cytome biomarkers KW - diagnosis KW - association KW - assay KW - life Y1 - 2020 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-231430 VL - 10 ER - TY - THES A1 - Gadeholt, Ottar T1 - Körperachsenorientierungsfehler - ein mit kognitiver Beeinträchtigung assoziiertes neues klinisches Zeichen T1 - Body axis orientation failure - a new clinical sign associated with cognitive impairment N2 - Diese Studie zeigt, dass eine Störung der Körperachsenorientierung, manifestiert dadurch, dass beim Hinlegen die Körperachse des Patienten von der Längsachse des Bettes abweicht, prädiktiv für eine kognitive Beeinträchtigung ist. N2 - This study shows that a failure of body axis orientation, expressed through a failure to align the longitudinal axis of the body to the longitudinal axis of the bed when lying down is predictive of cognitive impairment. KW - Körperachse KW - Demenz KW - kognitive Beeinträchtigung KW - body axis KW - dementia KW - cognitive impairment Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-71952 ER - TY - THES A1 - Wißmann, Saskia T1 - Evaluation kognitiver Störungen bei Patienten mit chronischer Hepatitis C unter Therapie mit Interferon-alpha und Ribavirin T1 - Evaluation of cognitive impairment in patients suffering from chronic hepatitis c during treatment with interferon-alpha and Ribavirin N2 - Patienten mit chronischer Hepatitis C in Behandlung mit Interferon-a als Monotherapie oder in Kombination mit dem Guaninanalogon Ribavirin wurden auf häufig geschilderte neurotoxische Nebenwirkungen, insbesondere kognitive Störungen sowie die Entwicklung von Symptomen eines depressiven Syndromes objektiv untersucht. Zur Evaluation der geschilderten Beschwerden dienten computergesteuerte neuropsychologische Testverfahren sowie etablierte psychometrische Testverfahren. 39 Patienten mit bioptisch gesicherter Hepatitis C nahmen an der regelmäßigen Datenerhebung vor, im Verlauf und nach Therapiebeendigung teil. Die psychometrischen Meßverfahren ergaben nahezu einheitlich statistisch signifikante Zunahmen von Depressivität, Angst und Aggressivität. In den neuropsychologischen Testverfahren bestätigen sich die häufig, jedoch bisher subjektiv beschriebenen kognitiven Störungen während einer Langzeittherapie mit Interferon-a auch objektiv. In erster Linie betroffen sind hierbei Vigilanz und Daueraufmerksamkeit. Insgesamt stellt sich das Maximum der Beeinträchtigungen zum dritten Meßzeitpunkt, d.h. drei Monate nach Therapiebeginn dar. Sowohl die kognitiven Störungen als auch die Entwicklung von Symptomen des depressiven Syndromes sind rasch reversibel. Therapiebedingte kognitive Defizite sind zumindest teilweise im Zusammenhang mit einer auftretenden Anämie als häufige Nebenwirkung des Ribavirins zu sehen. Die erfaßten kognitiven Defizite stehen jedoch nicht im Zusammenhang mit der depressiven Symptomatik. N2 - Patients suffering from hepatitis c, which were treated with interferon-a only or in combination together with Ribavirin were analyzed for the appearance of the often described neurotoxic side effects, in particular cognitive interferences and the development of a depressive syndrome in an objective manner. To evaluate the mentioned medical conditions, we used computerized neuropsychological tests and established psychometric test procedures. Data were collected from 39 patients suffering from chronic hepatitis c at different time points during the treatment. Psychometric data revealed a consistent increase of depression, fear and aggressiveness, which was statistically significant. In the neuropsychologic tests, we could validate the often, subjective described side effects during interferon-a treatment using objective criteria. Most notably, criteria like awakness and concentration are highly affected. Altogether, the highest levels of impairments are reached three months after the onset of the therapy. The cognitive interferences and the development of a depressive syndrome are rapid reversible during treatment. Cognitive deficits caused by therapy could be explained particularly by the appearance of blood anemia as a side effect of Ribavirin. The cognitive deficits, which were evaluated in this study, are not connected with the depressive pathology. KW - Chronische Hepatitis C KW - Interferon-a KW - Ribavirin KW - kognitive Störungen KW - Depressives Syndrom KW - Anämie KW - Chronic hepatitis c KW - interferon-a KW - Ribavirin KW - cognitive impairment KW - depressive syndrom KW - anemia KW - computerized neuropsychological tests Y1 - 2001 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-1182294 ER - TY - JOUR A1 - Traub, Jan A1 - Frey, Anna A1 - Störk, Stefan T1 - Chronic neuroinflammation and cognitive decline in patients with cardiac disease: evidence, relevance, and therapeutic implications JF - Life N2 - Acute and chronic cardiac disorders predispose to alterations in cognitive performance, ranging from mild cognitive impairment to overt dementia. Although this association is well-established, the factors inducing and accelerating cognitive decline beyond ageing and the intricate causal pathways and multilateral interdependencies involved remain poorly understood. Dysregulated and persistent inflammatory processes have been implicated as potentially causal mediators of the adverse consequences on brain function in patients with cardiac disease. Recent advances in positron emission tomography disclosed an enhanced level of neuroinflammation of cortical and subcortical brain regions as an important correlate of altered cognition in these patients. In preclinical and clinical investigations, the thereby involved domains and cell types of the brain are gradually better characterized. Microglia, resident myeloid cells of the central nervous system, appear to be of particular importance, as they are extremely sensitive to even subtle pathological alterations affecting their complex interplay with neighboring astrocytes, oligodendrocytes, infiltrating myeloid cells, and lymphocytes. Here, we review the current evidence linking cognitive impairment and chronic neuroinflammation in patients with various selected cardiac disorders including the aspect of chronic neuroinflammation as a potentially druggable target. KW - neuroinflammation KW - cognitive impairment KW - dementia KW - myocardial infarction KW - heart failure KW - hypertension KW - coronary artery disease KW - atrial fibrillation KW - cardiac arrest KW - aortic valve stenosis Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-304869 SN - 2075-1729 VL - 13 IS - 2 ER - TY - JOUR A1 - Hofmann, Lukas A1 - Karl, Franziska A1 - Sommer, Claudia A1 - Üçeyler, Nurcan T1 - Affective and cognitive behavior in the alpha-galactosidase A deficient mouse model of Fabry disease JF - PLoS ONE N2 - Fabry disease is an X-linked inherited lysosomal storage disorder with intracellular accumulation of globotriaosylceramide (Gb3) due to α-galactosidase A (α-Gal A) deficiency. Fabry patients frequently report of anxiety, depression, and impaired cognitive function. We characterized affective and cognitive phenotype of male mice with α-Gal A deficiency (Fabry KO) and compared results with those of age-matched male wildtype (WT) littermates. Young (3 months) and old (≥ 18 months) mice were tested in the naïve state and after i.pl. injection of complete Freund`s adjuvant (CFA) as an inflammatory pain model. We used the elevated plus maze (EPM), the light-dark box (LDB) and the open field test (OF) to investigate anxiety-like behavior. The forced swim test (FST) and Morris water maze (MWM) were applied to assess depressive-like and learning behavior. The EPM test revealed no intergroup difference for anxiety-like behavior in naïve young and old Fabry KO mice compared to WT littermates, except for longer time spent in open arms of the EPM for young WT mice compared to young Fabry KO mice (p<0.05). After CFA injection, young Fabry KO mice showed increased anxiety-like behavior compared to young WT littermates (p<0.05) and naïve young Fabry KO mice (p<0.05) in the EPM as reflected by shorter time spent in EPM open arms. There were no relevant differences in the LDB and the OF test, except for longer time spent in the center zone of the OF by young WT mice compared to young Fabry KO mice (p<0.05). Complementary to this, depression-like and learning behavior were not different between genotypes and age-groups, except for the expectedly lower memory performance in older age-groups compared to young mice. Our results indicate that genetic influences on affective and cognitive symptoms in FD may be of subordinate relevance, drawing attention to potential influences of environmental and epigenetic factors. KW - cognitive impairment KW - mouse models KW - depression KW - swimming KW - learning KW - Fabry disease KW - genetics Y1 - 2017 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-170745 VL - 12 IS - 6 ER -